Bristol Myers Squibb (BMY) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
Bristol Myers Squibb · Health Care · ref. ETF XLV · 53 calls · price $66.95
What the company does: Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio.
📈 Bristol Myers Squibb (BMY) stock price
$66.95+42.8% over range
Aug 28, 25low $42.6 · high $67.92Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 10 analysts
📊 JPI status : Bristol Myers Squibb has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 BMY price target & analyst consensus — price $66.95
The price target · all analysts combined (10 targets)
Highest target · 2 firms of 10$75+12.0%
Median target · of 10 targets$68+1.6%
Lowest target · 1 firm of 10$59-11.9%
Current price$66.95
Where these 10 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
550%
$70 ↔ $75
Below
550%
$59 ↔ $66
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: B of A Securities — 68% of its targets hit on this sector (356 calls tested). It aims for $66 (-1.4 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).
The 7 reliable analysts
$70+4.6 %
The 3 other firms
$60-10 %
How to read it: the 7 reliable firms are not filtered by optimism — 5 aim above the price, 2 below, hence their $70 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 10 ratings (last 6 months)
Strong Buy00%
Buy550%
Hold550%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 BMY price target all
All 53 calls, one by one, with our verdict on each firm.
→ See all 53 targets, analyst by analyst💡 The best analysts on BMY most reliable
The case for and against, with the numbers, per those who've been right on the stock.
→ Should you invest in BMY? The case for & againstAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Bristol Myers Squibb? The JPI assistant answers using our backtest data.
💰 Bristol Myers Squibb dividend: yield, history & growth › open the full page
4.43%annual yield
That's ~$2.50 per share per year.
📈 Bristol Myers Squibb fundamentals: valuation, margins & growth › open the full page
P/E 14.9Net margin 18.9 %Revenue growth +5.7 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 14 %
2023
Rev −2%Profit +27%
2024
Rev +7%Profit −212%
2025
Rev −0%
🔎 Detailed analyses
✅ Historical analyst reliability on BMY
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| William Blair ↗ | 100% | +44.2% | 3 |
| Goldman Sachs ↗ | 100% | +29.4% | 5 |
| Barclays ↗ | 100% | +11.2% | 5 |
| Raymond James ↗ | 100% | +9.0% | 2 |
| Morgan Stanley ↗ | 81% | +10.0% | 16 |
| Jefferies ↗ | 73% | +18.8% | 11 |
| BMO Capital ↗ | 67% | +10.3% | 15 |
| Berenberg ↗ | 67% | +0.1% | 3 |
| Credit Suisse | 67% | -0.5% | 3 |
| B of A Securities ↗ | 60% | +1.5% | 5 |
See the other 11 firms
| Cantor Fitzgerald ↗ | 0% | -21.6% | 4 |
| Guggenheim ↗ | 0% | -11.4% | 2 |
| UBS ↗ | 0% | -4.7% | 3 |
| Truist Securities ↗ | 20% | -7.2% | 5 |
| Atlantic Equities | 25% | -13.4% | 8 |
| Citigroup ↗ | 40% | -3.2% | 5 |
| JP Morgan ↗ | 40% | -0.1% | 5 |
| Argus Research ↗ | 50% | -2.2% | 2 |
| Leerink Swann | 50% | -1.0% | 6 |
| Societe Generale | 50% | +5.5% | 2 |
| Piper Sandler ↗ | 50% | +6.7% | 2 |
📊 What $1,000 invested in Bristol Myers Squibb would be worth › open the full page
In short — $1,000 invested in Bristol Myers Squibb 10 years ago would be worth $930 today, i.e. -1%/yr on average. Best year: 2024 (+17%), worst: 2023 (-26%). Price performance, excluding dividends.
If I'd invested $1,000 in Bristol Myers Squibb
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $966 | -3% |
| 3 years ago | $836 | -16% |
| 5 years ago | $940 | -6% |
Return by year (Bristol Myers Squibb)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -8% | $924 (-8%) |
| 2025 | +5% | $966 (-3%) |
| 2024 | +17% | $1,135 (+14%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Bristol Myers Squibb
Loading news…
📋 All analyst calls on BMY
Filtered on — · ✕ show all
Argus Research ↗
Aug 5, 26
▲ Buy · 🎯$75
Price at call : $64.15 — upside +17%
Today : $66.95 — upside +12%
🎯 on BMY : no call matured yet · 📊 on Health : 55.7% · +2.6% (158 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
■ Neutral neutral · not a buy · 🎯$70
Price at call : $65.89 — gap to target +6%
Today : $66.95 — gap to target +5%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
RBC Capital ↗
Jul 31, 26
■ Sector Perform neutral · not a buy · 🎯$64
Price at call : $65.47 — gap to target -2%
Today : $66.95 — gap to target -4%
🎯 on BMY : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 31, 27
matures : Jul 31, 27
▲ Overweight · 🎯$73
Price at call : $65.47 — upside +12%
Today : $66.95 — upside +9%
🎯 on BMY : no call matured yet · 📊 on Health : 53.8% · +5.3% (355 calls)
in progress (365j)
matures : Jul 31, 27
matures : Jul 31, 27
Cantor Fitzgerald ↗
Jul 31, 26
■ Neutral neutral · not a buy · 🎯$59
Price at call : $65.47 — gap to target -10%
Today : $66.95 — gap to target -12%
🎯 on BMY : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jul 31, 27
matures : Jul 31, 27
Wells Fargo ↗
Jul 31, 26
■ Equal-Weight neutral · not a buy · 🎯$65
Price at call : $65.47 — gap to target -1%
Today : $66.95 — gap to target -3%
🎯 on BMY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jul 31, 27
matures : Jul 31, 27
Guggenheim ↗
Jul 31, 26
▲ Buy · 🎯$75
Price at call : $65.47 — upside +15%
Today : $66.95 — upside +12%
🎯 on BMY : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Jul 31, 27
matures : Jul 31, 27
Truist Securities ↗
Jul 31, 26
▲ Buy · 🎯$70
Price at call : $65.31 — upside +7%
Today : $66.95 — upside +5%
🎯 on BMY : 0% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
in progress (365j)
matures : Jul 31, 27
matures : Jul 31, 27
See the other 45 calls, newest to oldest
B of A Securities ↗
Jul 10, 26
▲ Buy · 🎯$66
Price at call : $59.34 — upside +11%
Today : $66.95 — upside -1%
🎯 on BMY : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Jul 10, 27
matures : Jul 10, 27
Cantor Fitzgerald ↗
Jul 6, 26
■ Neutral neutral · not a buy · 🎯$54
Price at call : $56.7 — gap to target -5%
Today : $66.95 — gap to target -19%
🎯 on BMY : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Jul 6, 27
matures : Jul 6, 27
B of A Securities ↗
Apr 9, 26
▲ Buy · 🎯$67
Price at call : $58.62 — upside +14%
Today : $66.95 — upside +0%
🎯 on BMY : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Apr 9, 27
matures : Apr 9, 27
Guggenheim ↗
Apr 8, 26
▲ Buy · 🎯$72
Price at call : $59.2 — upside +22%
Today : $66.95 — upside +8%
🎯 on BMY : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Apr 8, 27
matures : Apr 8, 27
Cantor Fitzgerald ↗
Apr 8, 26
■ Neutral neutral · not a buy · 🎯$54
Price at call : $59.2 — gap to target -9%
Today : $66.95 — gap to target -19%
🎯 on BMY : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Apr 8, 27
matures : Apr 8, 27
■ Hold neutral · not a buy · 🎯$60
Price at call : $59.37 — gap to target +1%
Today : $66.95 — gap to target -10%
🎯 on BMY : no call matured yet · 📊 on Health : 53.6% · +1.4% (28 calls)
in progress (365j)
matures : Mar 17, 27
matures : Mar 17, 27
RBC Capital ↗
Feb 25, 26
■ Sector Perform neutral · not a buy · 🎯$60
Price at call : $61.1 — gap to target -2%
Today : $66.95 — gap to target -10%
🎯 on BMY : no call matured yet · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Feb 25, 27
matures : Feb 25, 27
Piper Sandler ↗
Feb 23, 26
▲ Overweight · 🎯$75
Price at call : $61.25 — upside +22%
Today : $66.95 — upside +12%
🎯 on BMY : 100% (1 call matured) · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Feb 23, 27
matures : Feb 23, 27
▲ Overweight · 🎯$75
Price at call : $61.25 — upside +22%
Today : $66.95 — upside +12%
🎯 on BMY : no call matured yet · 📊 on Health : 50.1% · +2.2% (629 calls)
in progress (365j)
matures : Feb 20, 27
matures : Feb 20, 27
■ Neutral neutral · not a buy · 🎯$64
Price at call : $60.77 — gap to target +5%
Today : $66.95 — gap to target -4%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
Wells Fargo ↗
Feb 6, 26
■ Equal-Weight neutral · not a buy · 🎯$60
Price at call : $60.77 — gap to target -1%
Today : $66.95 — gap to target -10%
🎯 on BMY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
Guggenheim ↗
Feb 6, 26
▲ Buy · 🎯$72
Price at call : $61.99 — upside +16%
Today : $66.95 — upside +8%
🎯 on BMY : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Feb 6, 27
matures : Feb 6, 27
Piper Sandler ↗
Jan 28, 26
▲ Overweight · 🎯$66
Price at call : $54.62 — upside +21%
Today : $66.95 — upside -1%
🎯 on BMY : 100% (1 call matured) · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Jan 28, 27
matures : Jan 28, 27
■ Neutral neutral · not a buy · 🎯$60
Price at call : $54.62 — gap to target +10%
Today : $66.95 — gap to target -10%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 27, 27
matures : Jan 27, 27
Leerink Partners ↗
Jan 13, 26
▲ Outperform · 🎯$60
Price at call : $57.02 — upside +5%
Today : $66.95 — upside -10%
🎯 on BMY : 0% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
in progress (365j)
matures : Jan 13, 27
matures : Jan 13, 27
Scotiabank ↗
Jan 9, 26
■ Sector Perform neutral · not a buy · 🎯$60
Price at call : $55.77 — gap to target +8%
Today : $66.95 — gap to target -10%
🎯 on BMY : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Jan 9, 27
matures : Jan 9, 27
■ Neutral neutral · not a buy · 🎯$53
Price at call : $55.9 — gap to target -5%
Today : $66.95 — gap to target -21%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 7, 27
matures : Jan 7, 27
▲ Buy · 🎯$65
Price at call : $55.9 — upside +16%
Today : $66.95 — upside -3%
🎯 on BMY : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Jan 7, 27
matures : Jan 7, 27
B of A Securities ↗
Dec 15, 25
▲ Buy · 🎯$61
Price at call : $54.29 — upside +12%
Today : $66.95 — upside -9%
🎯 on BMY : no call matured yet · 📊 on Health : 48.3% · +2.0% (356 calls)
in progress (365j)
matures : Dec 15, 26
matures : Dec 15, 26
Morgan Stanley ↗
Dec 12, 25
▼ Underweight · 🎯$37
Price at call : $54.29 — upside -32%
Today : $66.95 — upside -45%
🎯 on BMY : 50% (2 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
Guggenheim ↗
Dec 12, 25
▲ Buy · 🎯$62
Price at call : $52.41 — upside +18%
Today : $66.95 — upside -7%
🎯 on BMY : no call matured yet · 📊 on Health : 54.6% · +4.4% (97 calls)
in progress (365j)
matures : Dec 12, 26
matures : Dec 12, 26
Wells Fargo ↗
Dec 10, 25
■ Equal-Weight neutral · not a buy · 🎯$55
Price at call : $51.2 — gap to target +7%
Today : $66.95 — gap to target -18%
🎯 on BMY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Dec 10, 26
matures : Dec 10, 26
Scotiabank ↗
Dec 4, 25
■ Sector Perform neutral · not a buy · 🎯$53
Price at call : $52.15 — gap to target +2%
Today : $66.95 — gap to target -21%
🎯 on BMY : no call matured yet · 📊 on Health : 33.3% · -8.8% (9 calls)
in progress (365j)
matures : Dec 4, 26
matures : Dec 4, 26
Goldman Sachs ↗
Dec 2, 25
■ Neutral neutral · not a buy · 🎯$57
Price at call : $50.96 — gap to target +12%
Today : $66.95 — gap to target -15%
🎯 on BMY : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Dec 2, 26
matures : Dec 2, 26
■ Neutral neutral · not a buy · 🎯$45
Price at call : $47.06 — gap to target -4%
Today : $66.95 — gap to target -33%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Nov 17, 26
matures : Nov 17, 26
■ Neutral neutral · not a buy · 🎯$47
Price at call : $45.4 — gap to target +4%
Today : $66.95 — gap to target -30%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Aug 1, 26
matures : Aug 1, 26
Morgan Stanley ↗
Jul 10, 25
▼ Underweight · 🎯$34
Price at call : $46.86 — upside -27%
Today : $66.95 — upside -49%
Expected -27% · Actual +27% · Reason (≤ −15%) : ✗ No
🎯 on BMY : 50% (2 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
-26.6%
stock +27% · XLV +19%
matured Jul 10, 26
Wells Fargo ↗
Apr 28, 25
■ Equal-Weight neutral · not a buy · 🎯$53
Price at call : $49.22 — gap to target +8%
Today : $66.95 — gap to target -21%
🎯 on BMY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Apr 28, 26
matures : Apr 28, 26
Cantor Fitzgerald ↗
Apr 23, 25
■ Neutral neutral · not a buy · 🎯$55
Price at call : $48.69 — gap to target +13%
Today : $66.95 — gap to target -18%
🎯 on BMY : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Apr 23, 26
matures : Apr 23, 26
▲ Buy · 🎯$68
Price at call : $48.53 — upside +40%
Today : $66.95 — upside +2%
Expected +40% · Actual +22% · Reason (≥ +15%) : ✓ Yes
🎯 on BMY : 50% (2 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
+21.6%
stock +22% · XLV +8%
matured Apr 23, 26
Piper Sandler ↗
Apr 22, 25
▲ Overweight · 🎯$65
Price at call : $48.53 — upside +34%
Today : $66.95 — upside -3%
Expected +34% · Actual +22% · Reason (≥ +15%) : ✓ Yes
🎯 on BMY : 100% (1 call matured) · 📊 on Health : 46.7% · -1.3% (321 calls)
+21.6%
stock +22% · XLV +8%
matured Apr 22, 26
■ Neutral neutral · not a buy · 🎯$54
Price at call : $51.34 — gap to target +5%
Today : $66.95 — gap to target -19%
🎯 on BMY : no call matured yet · 📊 on Health : 51.5% · +3.1% (355 calls)
in progress (365j)
matures : Apr 11, 26
matures : Apr 11, 26
Goldman Sachs ↗
Apr 8, 25
■ Neutral neutral · not a buy · 🎯$55
Price at call : $53.74 — gap to target +2%
Today : $66.95 — gap to target -18%
🎯 on BMY : no call matured yet · 📊 on Health : 50.8% · +2.0% (240 calls)
in progress (365j)
matures : Apr 8, 26
matures : Apr 8, 26
Wells Fargo ↗
Feb 7, 25
■ Equal-Weight neutral · not a buy · 🎯$62
Price at call : $56.85 — gap to target +9%
Today : $66.95 — gap to target -7%
🎯 on BMY : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Feb 7, 26
matures : Feb 7, 26
Cantor Fitzgerald ↗
Feb 4, 25
■ Neutral neutral · not a buy · 🎯$55
Price at call : $59.12 — gap to target -7%
Today : $66.95 — gap to target -18%
🎯 on BMY : no call matured yet · 📊 on Health : 38.3% · -3.4% (342 calls)
in progress (365j)
matures : Feb 4, 26
matures : Feb 4, 26
■ Neutral neutral · not a buy · 🎯$65
Price at call : $58.76 — gap to target +11%
Today : $66.95 — gap to target -3%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jan 28, 26
matures : Jan 28, 26
Truist Securities ↗
Jan 8, 25
▲ Buy · 🎯$65
Price at call : $56.81 — upside +14%
Today : $66.95 — upside -3%
Expected +14% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on BMY : 0% (1 call matured) · 📊 on Health : 49.6% · +2.3% (260 calls)
-1.6%
stock -2% · XLV +13%
matured Jan 8, 26
▲ Buy · 🎯$70
Price at call : $55.87 — upside +25%
Today : $66.95 — upside +5%
Expected +25% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on BMY : 50% (2 calls matureds) · 📊 on Health : 50.8% · +4.5% (380 calls)
-2.9%
stock -3% · XLV +11%
matured Dec 16, 25
Wolfe Research ↗
Nov 15, 24
■ Peer Perform neutral · not a buy
🎯 on BMY : no call matured yet · 📊 on Health : 60.9% · +4.3% (46 calls)
in progress (365j)
matures : Nov 15, 25
matures : Nov 15, 25
■ Neutral neutral · not a buy · 🎯$60
Price at call : $58.41 — gap to target +3%
Today : $66.95 — gap to target -10%
🎯 on BMY : no call matured yet · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Nov 12, 25
matures : Nov 12, 25
BMO Capital ↗
Nov 12, 24
■ Market Perform neutral · not a buy · 🎯$61
Price at call : $58.41 — gap to target +4%
Today : $66.95 — gap to target -9%
🎯 on BMY : no call matured yet · 📊 on Health : 60.7% · +8.8% (239 calls)
in progress (365j)
matures : Nov 12, 25
matures : Nov 12, 25
Morgan Stanley ↗
Nov 12, 24
▼ Underweight · 🎯$39
Price at call : $59.02 — upside -34%
Today : $66.95 — upside -42%
Expected -34% · Actual -17% · Reason (≤ −15%) : ✓ Yes
🎯 on BMY : 50% (2 calls matureds) · 📊 on Health : 51.5% · +5.2% (825 calls)
+16.8%
stock -17% · XLV +4%
matured Nov 12, 25
Leerink Partners ↗
Nov 12, 24
▲ Outperform · 🎯$73
Price at call : $59.02 — upside +24%
Today : $66.95 — upside +9%
Expected +24% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on BMY : 0% (1 call matured) · 📊 on Health : 55.3% · -4.8% (38 calls)
-16.8%
stock -17% · XLV +4%
matured Nov 12, 25
Daiwa Capital ↗
Nov 2, 23
■ Neutral neutral · not a buy · 🎯$54
Price at call : $52.82 — gap to target +2%
Today : $66.95 — gap to target -19%
🎯 on BMY : no call matured yet · 📊 on Health : 40% · -1.0% (5 calls)
in progress (365j)
matures : Nov 1, 24
matures : Nov 1, 24
Frequently asked questions
Should I buy Bristol Myers Squibb stock?
This isn't buy advice. For Bristol Myers Squibb, the analyst consensus is "Buy", with an average price target of $68.00 (+2% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (3 calls tracked on Bristol Myers Squibb). We show the numbers — you decide.
Is it too late to buy Bristol Myers Squibb? How high can it go?
The most bullish analyst target on Bristol Myers Squibb is $75.00 (+12% above today's price); the average is $68.00. That's the upside they see. Check how reliable those analysts have actually been on Bristol Myers Squibb on our site before trusting it.
Is Bristol Myers Squibb still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 21 analysts have a real record on Bristol Myers Squibb, the best hitting 100% over 3 calls. Current consensus: "Buy". Make your call on data, not noise.
Should you invest in Bristol Myers Squibb? The case for and against
The arguments for and against, one by one, from the numbers: why invest in BMY (and why hesitate).
What has Bristol Myers Squibb's past performance been?
Historical returns and a "how much if I had invested" calculator: BMY performance & returns.
Does Bristol Myers Squibb pay a dividend?
Yield, consistency and growth history of the dividend: BMY's dividend.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX